The disease burden of current neurological disorders , including degenerative, genetic and neurotoxic, require the development of new standards for drug development.
To meet this need, Axiogenesis has developed human induced pluripotent stem cell (iPSC) derived dopaminergic neurons – Dopa.4UTM.

Dopa.4UTM represent an excellent in vitro model for efficacy, safety and toxicology studies with the following advantages:

  • Fully differentiated, primary-like morphological, electrophysiological and pharmacological characteristics
  • Long-term viability (> 50 days in culture)
  • Ready-to-use (just thaw and plate)
  • Quickly to implement: only 3 days pre-culture required post-thaw
  • Suitable for HTS
  • Applicable for drug development given presence of functional toxicity pathways (e.g. Parkinson’s Disease – MPP+, 6-OHDA)

Dopa.4UTM have been validated in the following assays and applications:

  • Immunocytochemistry
  • Manual and automated patch clamp    [ Poster ]
  • Microelectrode array (MEA)    [ Poster 1 ] [ Poster 2 ]
  • Calcium transients
  • Neurite outgrowth assay (high content analysis)

For sales inquiries and data requests, contact us at order@axiogenesis.com.

Next day delivery is available for both European and US customers.

Order Information Dopa.4U

Ax-B-HD02-2M: 2 x 10^6 frozen cells (vial)